信号转导及转录激活因子3(signal transducers and activators of transcription 3,STAT3)是一种细胞内重要的转录因子,在体内可被其最常见的上游激酶JAK激酶(Janus kinase)磷酸化激活。众所周知,异常激活的STAT3促进肿瘤的发生发展,因...信号转导及转录激活因子3(signal transducers and activators of transcription 3,STAT3)是一种细胞内重要的转录因子,在体内可被其最常见的上游激酶JAK激酶(Janus kinase)磷酸化激活。众所周知,异常激活的STAT3促进肿瘤的发生发展,因此研究人员一直致力于研究一类靶向JAK/STAT3信号通路的抗肿瘤药物。笔者收集了近年来文献中报道的靶向JAK/STAT3信号通路的抑制剂研究及临床试验进展,对于部分抑制剂已经报道的靶点、作用机制和药效活性进行总结。展开更多
Janus激酶/信号转导与转录激活因子(janus kinase/signal transducer and activator of transcription,JAK/STAT)信号通路是众多细胞因子信号转导的共同途径,广泛参与细胞增殖、分化、凋亡以及炎症等过程,可以通过负调节因子、与其他信...Janus激酶/信号转导与转录激活因子(janus kinase/signal transducer and activator of transcription,JAK/STAT)信号通路是众多细胞因子信号转导的共同途径,广泛参与细胞增殖、分化、凋亡以及炎症等过程,可以通过负调节因子、与其他信号通路相互作用、STATs共价修饰等多种途径进行调节。JAK/STAT通路的激活促进各种疾病的发生发展,包括各种实体肿瘤、淋巴瘤、白血病以及炎症性疾病等。针对JAK/STAT信号通路及其抑制剂的研究有助于肺癌的预防和治疗。本文主要就JAK/STAT信号通路与肺癌的关系及针对此通路的靶向治疗做一综述。展开更多
Recent advances in molecular targeted therapies, including targeting human epidermal growth factor receptor 2(HER2), had a major forward step in the therapy for gastric cancer patients. Application of HER2-targeted th...Recent advances in molecular targeted therapies, including targeting human epidermal growth factor receptor 2(HER2), had a major forward step in the therapy for gastric cancer patients. Application of HER2-targeted therapies, in particular trastuzumab in combination with chemotherapy in metastatic HER2-positive gastric cancers, resulted in improvements in response rates, time to progression and overall survival. Nevertheless, as with breast cancer, many patients with gastric cancer develop resistance to trastuzumab. Several promising therapies are currently being developed in combination with chemotherapy to increase the efficacy and overcome the cancerresistance. Here we review the current overview of clinical application of agents targeting HER2 in gastric cancer. We also discuss the ongoing trials supporting the use of HER2-targeted agents combined with cytotoxic agents or other monoclonal antibodies.展开更多
文摘信号转导及转录激活因子3(signal transducers and activators of transcription 3,STAT3)是一种细胞内重要的转录因子,在体内可被其最常见的上游激酶JAK激酶(Janus kinase)磷酸化激活。众所周知,异常激活的STAT3促进肿瘤的发生发展,因此研究人员一直致力于研究一类靶向JAK/STAT3信号通路的抗肿瘤药物。笔者收集了近年来文献中报道的靶向JAK/STAT3信号通路的抑制剂研究及临床试验进展,对于部分抑制剂已经报道的靶点、作用机制和药效活性进行总结。
文摘Janus激酶/信号转导与转录激活因子(janus kinase/signal transducer and activator of transcription,JAK/STAT)信号通路是众多细胞因子信号转导的共同途径,广泛参与细胞增殖、分化、凋亡以及炎症等过程,可以通过负调节因子、与其他信号通路相互作用、STATs共价修饰等多种途径进行调节。JAK/STAT通路的激活促进各种疾病的发生发展,包括各种实体肿瘤、淋巴瘤、白血病以及炎症性疾病等。针对JAK/STAT信号通路及其抑制剂的研究有助于肺癌的预防和治疗。本文主要就JAK/STAT信号通路与肺癌的关系及针对此通路的靶向治疗做一综述。
基金KAKENHI(Grant-in-Aid for Scientific Research),No.23390329the National Cancer Center Research and Development Fund(23-A-9)
文摘Recent advances in molecular targeted therapies, including targeting human epidermal growth factor receptor 2(HER2), had a major forward step in the therapy for gastric cancer patients. Application of HER2-targeted therapies, in particular trastuzumab in combination with chemotherapy in metastatic HER2-positive gastric cancers, resulted in improvements in response rates, time to progression and overall survival. Nevertheless, as with breast cancer, many patients with gastric cancer develop resistance to trastuzumab. Several promising therapies are currently being developed in combination with chemotherapy to increase the efficacy and overcome the cancerresistance. Here we review the current overview of clinical application of agents targeting HER2 in gastric cancer. We also discuss the ongoing trials supporting the use of HER2-targeted agents combined with cytotoxic agents or other monoclonal antibodies.
